EP Patent

EP3184526A1 — Pyrrolo[2,3-d]pyrimidine derivatives as janus kinase inhibitor

Assigned to Incyte Holdings Corp · Expires 2017-06-28 · 9y expired

What this patent protects

The present invention provides deuterated derivatives of the compounds These derivatives modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, …

USPTO Abstract

The present invention provides deuterated derivatives of the compounds These derivatives modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.

Drugs covered by this patent

Patent Metadata

Patent number
EP3184526A1
Jurisdiction
EP
Classification
—
Expires
2017-06-28
Drug substance claim
No
Drug product claim
No
Assignee
Incyte Holdings Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.